var data={"title":"Aminophylline: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Aminophylline: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5615?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=aminophylline-patient-drug-information\" class=\"drug drug_patient\">see &quot;Aminophylline: Patient drug information&quot;</a> and <a href=\"topic.htm?path=aminophylline-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Aminophylline: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133450\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Aminophylline Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133493\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Phosphodiesterase Enzyme Inhibitor, Nonselective</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133454\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> All dosages expressed as <b>aminophylline</b>; use <b>ideal body weight</b> (theophylline distributes poorly into body fat) to calculate dose; individualize dose based on steady-state serum concentrations. Theophylline dose is ~79% of aminophylline dose. The treatment of asthma exacerbations with aminophylline is not supported or recommended by current clinical practice guidelines (GINA 2016; NAEPP 2007). The treatment of acute COPD exacerbations with aminophylline is not recommended by current clinical practice guidelines (Global Initiative for COPD Guidelines 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Reversible airflow obstruction, acute symptoms: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Loading dose:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Patients who have not received aminophylline or theophylline in the previous 24 hours:</b> 5.7 mg/kg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Patients who have received aminophylline or theophylline in the previous 24 hours:</b> A loading dose should not be given before obtaining a serum theophylline concentration. The loading dose should be calculated as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose = (desired serum theophylline concentration - measured serum theophylline concentration) (V<sub>d</sub>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Maintenance dose:</b> IV: <b>Note:</b> Dosing presented is to achieve a target theophylline concentration of 10 mcg/mL. Lower initial doses may be required in patients with reduced theophylline clearance. Dosage should be adjusted according to serum level measurements.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &le;60 years: 0.51 mg/kg/hour; maximum dose: 1,139 mg/day unless serum levels indicate need for larger dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &gt;60 years: 0.38 mg/kg/hour; maximum dose: 507 mg/day unless serum levels indicate need for larger dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiac decompensation, cor pulmonale, sepsis with multiorgan failure, and shock: 0.25 mg/kg/hour; maximum dose: 507 mg/day unless serum levels indicate need for larger dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment based on serum theophylline concentrations:</b> <b>Note:</b> Recheck serum theophylline concentration 24 hours after dosage adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;9.9 mcg/mL: If dosage is tolerated, but symptoms are not controlled, increase infusion rate ~25%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">10 to 14.9 mcg/mL: Maintain infusion rate if dosage is tolerated and symptoms controlled. Recheck serum concentrations at 24-hour intervals. If symptoms are not controlled and dosage is tolerated, consider adding additional medications to treatment regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">15 to 19.9 mcg/mL: Consider 10% dose reduction in infusion rate to improve safety margin even if dose is tolerated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">20 to 24.9 mcg/mL: Decrease infusion rate by 25% even if no adverse effects present.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">25 to 30 mcg/mL: Stop infusion for 24 hours and decrease subsequent infusion rate at least 25%. If symptomatic, stop infusion and consider whether overdose treatment is indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;30 mcg/mL: Stop infusion and treat overdose; if resumed, decrease subsequent infusion rate at least 50%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Reversal of adenosine-, dipyridamole-, or regadenoson-induced adverse reactions (eg, angina, hypotension) during nuclear cardiac stress testing (off-label use):</b> IV: 50 to 250 mg administered over 30 to 60 seconds, repeat as necessary. <b>Note:</b> Since adenosine-induced side effects are short lived after discontinuation of the infusion, aminophylline administration is only very rarely required (ASNC [Henzlova 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133474\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=aminophylline-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Aminophylline: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> All dosages expressed as <b>aminophylline</b>; use <b>ideal body weight</b> (theophylline distributes poorly into body fat) to calculate dose; individualize dose based on steady-state serum concentrations. Theophylline dose is ~79% of aminophylline dose. The treatment of asthma exacerbations with aminophylline is not supported or recommended by current clinical practice guidelines (GINA 2016; NAEPP 2007). The treatment of acute COPD exacerbations with aminophylline is not recommended by current clinical practice guidelines (Global Initiative for COPD Guidelines 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Reversible airflow obstruction</b>\n      <b>, acute symptoms: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Loading dose:</b> IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Maintenance dose:</b> IV: <b>Note:</b> Dosing presented is to achieve a target theophylline concentration of 10 mcg/mL unless otherwise noted. Lower initial doses may be required in patients with reduced theophylline clearance. Dosage should be adjusted according to serum level measurements.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 4 to 6 weeks: 1.9 mg/kg/dose every 12 hours (to achieve a target concentration of 7.5 mcg/mL for neonatal apnea).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 6 to 52 weeks: Dose (mg/kg/hour) = [(0.008 x age in weeks) + 0.21] divided by 0.79</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to &lt;9 years: 1.01 mg/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 9 to &lt;12 years: 0.89 mg/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents 12 to &lt;16 years (cigarette or marijuana smokers): 0.89 mg/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents 12 to &lt;16 years (nonsmokers): 0.63 mg/kg/hour; maximum dose: 1,139 mg/day unless serum levels indicate need for larger dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;16 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiac decompensation, cor pulmonale, sepsis with multiorgan failure, and shock: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment based on serum theophylline concentrations:</b> <b>Note:</b> Recheck serum theophylline concentration 12 hours after dosage adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;9.9 mcg/mL: If dosage is tolerated, but symptoms are not controlled, increase infusion rate ~25%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">10 to 14.9 mcg/mL: Maintain infusion rate if dosage is tolerated and symptoms controlled. Recheck serum concentrations at 24-hour intervals. If symptoms are not controlled and dosage is tolerated, consider adding additional medications to treatment regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">15 to 19.9 mcg/mL: Consider 10% dose reduction in infusion rate to improve safety margin even if dose is tolerated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">20 to 24.9 mcg/mL: Decrease infusion rate by 25% even if no adverse effects present.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">25 to 30 mcg/mL: Stop infusion for 12 hours and decrease subsequent infusion rate at least 25%. If symptomatic, stop infusion and consider whether overdose treatment is indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;30 mcg/mL: Stop infusion and treat overdose; if resumed, decrease subsequent infusion rate at least 50%.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133455\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Maximum dose: 507 mg/day unless serum levels indicate need for a larger dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682648\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants 1 to 3 months: There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; however dose reduction and frequent monitoring of serum theophylline concentrations required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants &gt;3 months, Children, Adolescents, and Adults: No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682649\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Infants, Children, Adolescents, and Adults: Initial: 0.25 mg/kg/hour; maximum dose: 507 mg/day unless serum concentrations indicate need for larger dose. Use with caution and monitor serum theophylline concentrations frequently.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133426\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as dihydrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg/mL (10 mL, 20 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133412\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10903090\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution [preservative free]: 25 mg/mL (10 mL); 50 mg/mL (10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133429\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: For IV administration only. Loading doses should be administered IV over 30 minutes. Infusion rate should not exceed 21 mg/hour in patients with cor pulmonale, cardiac decompensation, hepatic impairment, patients &gt;60 years, or patients taking medications which reduce theophylline clearance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Off-label use: For reversal of adenosine-, dipyridamole-, or regadenoson-induced adverse events during nuclear cardiac stress testing, administer IV undiluted over 30 to 60 seconds, repeat as necessary. Since adenosine-induced side effects are short lived after discontinuation of the infusion, aminophylline administration is only very rarely required (ASNC [Henzlova 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote; remove needle/cannula; apply dry cold compresses (Hurst 2004; Reynolds 2014); elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hyaluronidase:</i> Intradermal or SubQ: Inject a total of 1 to 1.7 mL (15 units/mL) as five separate 0.2 to 0.3 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara 1983; Reynolds 2014; Zenk 1981).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471280\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 250 mg in 250 mL (concentration: 1 mg/mL) of D<sub>5</sub>W or NS </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471281\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 1 mg/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133427\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Reversible airflow obstruction: </b>Treatment of acute exacerbations of symptoms and reversible airflow obstruction due to asthma or other chronic lung diseases (eg, emphysema, chronic bronchitis) as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Guideline recommendations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Asthma:</b> The 2007 National Heart, Lung, and Blood Institute Asthma Guidelines and the 2016 Global Initiative for Asthma Guidelines (GINA) recommend against aminophylline for the treatment of asthma exacerbations because of poor efficacy and safety concerns (GINA 2016; NAEPP 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>COPD:</b> The 2017 Global Initiative for Chronic Obstructive Lung Disease Guidelines recommends against aminophylline for the treatment of COPD exacerbations because of significant adverse effects (GOLD 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25721925\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Reversal of adenosine-, dipyridamole-, or regadenoson-induced adverse reactions (eg, angina, hypotension) during nuclear cardiac stress testing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133500\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Aminophylline may be confused with amitriptyline, ampicillin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133419\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. Adverse events observed at therapeutic serum levels:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache, insomnia, irritability, restlessness, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Allergic skin reaction, exfoliative dermatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Diuresis (transient)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tremor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133432\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to aminophylline, theophylline, ethylenediamine, or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Coronary artery disease where cardiac stimulation might prove harmful; peptic ulcer disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133416\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant; ensure proper catheter or needle position prior to and during infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Theophylline toxicity: Severe and potentially fatal theophylline toxicity may occur if reduced theophylline clearance occurs. Theophylline clearance may be decreased in patients with acute pulmonary edema, heart failure, cor pulmonale, fever (&ge;102&deg;F for &ge;24 hours or lesser temperature elevations for longer periods), hepatic disease, acute hepatitis, cirrhosis, hypothyroidism, sepsis with multiorgan failure, shock, neonates (term and premature), infants &lt;3 months of age with decreased renal function, infants &lt;1 year, elderly &gt;60 years, and patients following cessation of smoking. Consider benefits versus risks and the need for more intensive monitoring in these patients; reduced infusion rate required. If a patient develops signs and symptoms of theophylline toxicity (eg, nausea or persistent, repetitive vomiting), a serum theophylline level should be measured immediately and subsequent doses withheld.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiac arrhythmias (excluding bradyarrhythmias); use may exacerbate arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cystic fibrosis: Use with caution in patients with cystic fibrosis; increased theophylline clearance may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment (eg, cirrhosis, acute hepatitis, cholestasis); risk of severe and potentially fatal theophylline toxicity is increased. Theophylline clearance is decreased &ge;50% in these patients. Dose reduction and frequent monitoring of serum theophylline concentrations are required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism; increased theophylline clearance may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peptic ulcer disease: Use with caution in patients with active peptic ulcer disease; use may exacerbate peptic ulcer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with seizure disorders; use may exacerbate seizure disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Special populations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use extreme caution in the elderly; these patients are at greater risk of serious theophylline toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Select dose with caution and with frequent monitoring of concentrations (especially &lt;1 year); rate of clearance is highly variable in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Do not increase dose in response to acute exacerbation of symptoms unless steady state serum theophylline concentration is &lt;10 mcg/mL. As the rate of theophylline clearance may be dose-dependent, an increase in dose based upon a subtherapeutic serum concentration measurement should be limited to ~25% increase of the previous infusion rate or daily dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133489\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (major), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133420\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8620&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acebrophylline: May enhance the stimulatory effect of Theophylline Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adalimumab: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adenosine: Theophylline Derivatives may diminish the therapeutic effect of Adenosine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May increase the serum concentration of Aminophylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antithyroid Agents: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzodiazepines: Theophylline Derivatives may diminish the therapeutic effect of Benzodiazepines. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Theophylline Derivatives. Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Theophylline Derivatives.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Theophylline Derivatives. Theophylline Derivatives may decrease the serum concentration of CarBAMazepine. Management: Seek alternatives to this combination when possible.  If these agents are used together, monitor closely for decreased serum concentrations/therapeutic effects of both medications.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May decrease the metabolism of Theophylline Derivatives.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inducers (Moderate): May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproterone: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disulfiram: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Theophylline Derivatives may enhance the adverse/toxic effect of Doxofylline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Febuxostat: May increase serum concentrations of the active metabolite(s) of Theophylline Derivatives. Specifically, concentrations of 1-methylxanthine, a metabolite of unknown clinical importance, may become elevated.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May decrease the metabolism of Theophylline Derivatives.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Formoterol: Theophylline Derivatives may enhance the adverse/toxic effect of Formoterol. Theophylline Derivatives may enhance the hypokalemic effect of Formoterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Theophylline Derivatives. Theophylline Derivatives may decrease the serum concentration of Fosphenytoin. Management: Seek alternatives when possible. If used together, monitor for decreased concentrations/effects of phenytoin or theophylline if the other agent is initiated/dose increased, or increased concentrations/effects if the other is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indacaterol: Theophylline Derivatives may enhance the adverse/toxic effect of Indacaterol. Theophylline Derivatives may enhance the hypokalemic effect of Indacaterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Interferons: May decrease the metabolism of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoproterenol: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Theophylline Derivatives may decrease the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May decrease the metabolism of Theophylline Derivatives.<b> Exceptions: </b>Azithromycin (Systemic); Fidaxomicin; Roxithromycin; Spiramycin; Telithromycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mexiletine: May decrease the metabolism of Theophylline Derivatives.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olodaterol: Theophylline Derivatives may enhance the adverse/toxic effect of Olodaterol. Theophylline Derivatives may enhance the hypokalemic effect of Olodaterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pancuronium: Theophylline Derivatives may enhance the adverse/toxic effect of Pancuronium. Theophylline Derivatives may diminish the neuromuscular-blocking effect of Pancuronium.  Management: Pancuronium dosage adjustment may be necessary to induce paralysis  in patients receiving concomitant theophylline derivatives. Monitor closely for adverse effects (e.g., cardiac effects) with concomitant use of these agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Theophylline Derivatives. Theophylline Derivatives may decrease the serum concentration of Phenytoin. Management: Seek alternatives when possible. If used together, monitor for decreased concentrations/effects of phenytoin or theophylline if the other agent is initiated/dose increased, or increased concentrations/effects if the other is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May decrease the serum concentration of Theophylline Derivatives.<b> Exceptions: </b>Fosamprenavir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May decrease the metabolism of Theophylline Derivatives. Ciprofloxacin and enoxacin are of greatest concern.  Theophylline/quinolone therapy might augment the seizure-producing potential of each of the individual agents.<b> Exceptions: </b>Delafloxacin; Gemifloxacin; LevoFLOXacin (Systemic); Lomefloxacin; Moxifloxacin (Systemic); Nalidixic Acid; Pefloxacin; Sparfloxacin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regadenoson: Aminophylline may diminish the vasodilatory effect of Regadenoson. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Theophylline Derivatives may enhance the hypotensive effect of Riociguat. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfinpyrazone: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiabendazole: May decrease the metabolism of Theophylline Derivatives.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopental: Aminophylline may diminish the therapeutic effect of Thiopental. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: May increase the metabolism of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticlopidine: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zafirlukast: Theophylline Derivatives may decrease the serum concentration of Zafirlukast. Zafirlukast may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zileuton: May increase the serum concentration of Aminophylline. Management: Reduce aminophylline dose by 50% upon initiation of zileuton therapy. If aminophylline is added to existing zileuton therapy, use a lower starting dose. Monitor for increased theophylline serum concentrations and effects.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133447\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethanol: Ethanol may decrease theophylline clearance. Management: Avoid or limit ethanol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Food: Theophylline clearance is increased and half-life decreased by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled beef; a high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of theophylline. Management: Avoid extremes of dietary protein and carbohydrate intake.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133422\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133436\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. Theophylline crosses the placenta. Refer to Theophylline monograph for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133437\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Theophylline is present in breast milk. Refer to Theophylline monograph for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10903064\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heart rate; CNS effects (insomnia, irritability); respiratory rate (COPD patients often have resting controlled respiratory rates in low 20s); arterial or capillary blood gases (if applicable)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline levels: Serum theophylline levels should be monitored after initiation of therapy and prior to making dose increases; in the presence of signs or symptoms of toxicity; or when a new illness, worsening of a present illness, or change in patient&rsquo;s treatment regimen that may alter theophylline clearance (eg, fever <i>&gt;</i>102&deg;F or sustained for 24 hours or more, hepatitis, or drugs that are added or discontinued); changes in fluid balance; electrolyte concentrations, acid-base balance during prolonged therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Loading dose: Measure serum concentrations 30 minutes after the end of an IV loading dose in patients who have not received theophylline in the previous 24 hours to determine the need for an additional loading (serum concentration &lt;10 mcg/mL) or to delay starting the constant IV infusion (serum concentration &gt;20 mcg/mL).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infusion: Measure serum concentrations one half-life (eg, ~4 hours in children 1 to 9 years of age or 8 hours in nonsmoking, otherwise healthy adults) after starting a continuous infusion, then every 12 to 24 hours for duration of infusion; measure more frequently in acutely ill patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Monitor infusion site.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10903087\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Therapeutic levels:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: 5 to 15 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 10 to 20 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Toxic concentration: &gt;20 mcg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133415\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Theophylline has two distinct actions; smooth muscle relaxation (ie, bronchodilation) and suppression of the response of the airways to stimuli (ie, non-bronchodilator prophylactic effects). Bronchodilation is mediated by inhibition of two isoenzymes, phosphodiesterase (PDE III and, to a lesser extent, PDE IV) while non-bronchodilation effects are mediated through other molecular mechanisms. Theophylline increases the force of contraction of diaphragmatic muscles through enhancement of calcium uptake through adenosine-mediated channels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133431\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Theophylline:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Theophylline: ~0.45 L/kg based on ideal body weight; distributes poorly into body fat; V<sub>d</sub> may increase in premature neonates, hepatic cirrhosis, acidemia (uncorrected), elderly, and third trimester of pregnancy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Theophylline: ~40%, primarily to albumin; decreased in neonates (due to a greater percentage of fetal albumin), hepatic cirrhosis, acidemia (uncorrected), elderly, third trimester of pregnancy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Theophylline: Hepatic via demethylation (CYP 1A2) and hydroxylation (CYP 2E1 and 3A4); forms active metabolites (caffeine and 3-methylxanthine)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Theophylline: Highly variable and dependent upon age, hepatic function, cardiac function, lung disease, and smoking history</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premature infants, postnatal age 3 to 15 days: 30 hours (range: 17 to 43 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premature infants, postnatal age 25 to 57 days: 20 hours (range: 9.4 to 30.6 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Term infants, postnatal age 1 to 2 days: 25.7 hours (range: 25 to 26.5 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Term infants, postnatal age 3 to 30 weeks: 11 hours (range: 6 to 29 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 to 4 years: 3.4 hours (range: 1.2 to 5.6 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents 6 to 17 years: 3.7 hours (range: 1.5 to 5.9 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults &ge;18 years to &le;60 years (asthma, nonsmoking, otherwise healthy): 8.7 hours (range: 6.1 to 12.8 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Elderly &gt;60 years (nonsmoking, healthy): 9.8 hours (range: 1.6 to 18 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance: Certain conditions may significantly alter theophylline clearance; severe and potentially fatal theophylline toxicity may occur if reduced theophylline clearance occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Decreased theophylline clearance: Neonates and infants; elderly &gt;60 years; acute pulmonary edema, cor pulmonale; fever (&ge;102&deg;F for &ge;24 hours or lesser temperature elevations for longer periods); heart failure; hepatic impairment (eg, cirrhosis, acute hepatitis, cholestasis); hypothyroidism; patients following cessation of smoking; sepsis with multiple organ failure; shock; third trimester of pregnancy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Increased theophylline clearance: Hyperthyroidism; cystic fibrosis; smoking (ie, marijuana or tobacco).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Within 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Theophylline: Urine (~50% as unchanged drug [Neonates]; ~10% as unchanged drug [Infants &gt;3 months, Adolescents, and Adults])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133435\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aminophylline Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (10 mL): $0.82</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133438\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aminocont (FI);</li>\n      <li>Aminofilina (CO, CR, DO, EC, GT, HN, NI, PA, PL, SV);</li>\n      <li>Aminomal (CH, IT);</li>\n      <li>Aminophyllin (HR, NO);</li>\n      <li>Aminophylline Renaudin (FR);</li>\n      <li>Aminophyllinum (PL);</li>\n      <li>Aminophyllinum Prolongatum (PL);</li>\n      <li>Aminophyllinum Retard (HU, PL);</li>\n      <li>Aminoslow (LU);</li>\n      <li>Aminosol (PH);</li>\n      <li>Amlin (KR);</li>\n      <li>Asiphylline (TW);</li>\n      <li>Asmafilin (TR);</li>\n      <li>Asmafin (TR);</li>\n      <li>Asmapen (BR);</li>\n      <li>Asthcontin (KR);</li>\n      <li>Brolin (BD);</li>\n      <li>Cardiomin (CL);</li>\n      <li>Cardirenal (AR);</li>\n      <li>Cardophyllin (AU);</li>\n      <li>Carine (AU);</li>\n      <li>Clonofillin SR (HU);</li>\n      <li>Diaphyllin (HU, VN);</li>\n      <li>Escophyllin (CH);</li>\n      <li>Euphyllin (AT, BE, BH, CH, DE, LU, NL, SA);</li>\n      <li>Euphyllin Retard (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Filin (BD);</li>\n      <li>Filotempo (PT);</li>\n      <li>Lanrox (BD);</li>\n      <li>Minophyl (IN);</li>\n      <li>Minoton (BR);</li>\n      <li>Miofilin (RO);</li>\n      <li>Neophyllin (JP, QA, SG);</li>\n      <li>Pediatric Asthcontin for Children SR (KR);</li>\n      <li>Peterphyllin (ZA);</li>\n      <li>Phaminov (ID, PH);</li>\n      <li>Pharmafil (MX);</li>\n      <li>Phylin (BD);</li>\n      <li>Phyllocontin (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GB, GH, GM, GN, GY, ID, IE, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, PK, QA, SA, SC, SD, SL, SN, SR, SY, TN, TR, TT, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Phyllocontin Continus (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Phyllotemp (CH, DE, GR);</li>\n      <li>Planphylline (FR);</li>\n      <li>Retafilin (HR);</li>\n      <li>Sofafyllin (BG);</li>\n      <li>Syntophyllin (CZ);</li>\n      <li>Tefamin (IT);</li>\n      <li>Teofyllamin Ipex (SE);</li>\n      <li>Xing You Shan (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Society of Nuclear Cardiology, &ldquo;Imaging Guidelines for Nuclear Cardiology Procedures: A Report of The American Society of Nuclear Cardiology Quality Assurance Committee,&rdquo; <i>J Nucl Cardiol</i>, 2006, 13(6):e21-171.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aminophylline [prescribing information]. Lake Forest, IL: Hospira Inc; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2016. Available at: http://www.ginasthma.org. Accessed June 22, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2017. Available at http://www.goldcopd.com.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Henzlova MJ, Duvall WL, Einstein AJ, et al. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers published correction appears in <i>J Nucl Cardiol</i>. 2016; 23(3):640-642. <i>J Nucl Cardiol</i>. 2016; 23(3):606-639.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hersh EV. Adverse drug interactions in dental practice: interactions involving antibiotics. Part II of a series. <i>J Am Dental Assoc.</i> 1999;130(2):236-251.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminophylline-drug-information/abstract-text/10036847/pubmed\" target=\"_blank\" id=\"10036847\">10036847</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminophylline-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klocke FJ, Baird MG, Lorell BH, et al, &ldquo;ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging),&rdquo; <i>J Am Coll Cardiol</i>, 2003, 42(7):1318-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminophylline-drug-information/abstract-text/14522503/pubmed\" target=\"_blank\" id=\"14522503\">14522503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminophylline-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 08-4051. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2007. <a href=\"http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf</a>. Accessed June 22, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ranhosky A and Kempthorne-Rawson J, &ldquo;The Safety of Intravenous Dipyridamole Thallium Myocardial Perfusion Imaging. Intravenous Dipyridamole Thallium Imaging Study Group,&rdquo; <i>Circulation</i>, 1990, 81(4):1205-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminophylline-drug-information/abstract-text/2107985/pubmed\" target=\"_blank\" id=\"2107985\">2107985</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminophylline-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8620 Version 181.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F133450\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F133493\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F133454\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F133474\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F133455\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15682648\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682649\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F133426\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F133412\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F10903090\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F133429\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14471280\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14471281\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F133427\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25721925\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F133500\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F133419\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F133432\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F133416\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F133489\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F133420\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F133447\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F133422\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F133436\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F133437\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10903064\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F10903087\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F133415\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F133431\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F133435\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F133438\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8620|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=aminophylline-patient-drug-information\" class=\"drug drug_patient\">Aminophylline: Patient drug information</a></li><li><a href=\"topic.htm?path=aminophylline-pediatric-drug-information\" class=\"drug drug_pediatric\">Aminophylline: Pediatric drug information</a></li></ul></div></div>","javascript":null}